Biliary Tract Cancer Fail Is Another Blow for Merck KGaA/GSK's Bintrafusp
Objective Response Rate Too Low For Filing
Less than two months after bintrafusp failed to beat Merck & Co's blockbuster Keytruda in a Phase III NSCLC trial, Merck KGaA's bispecific fusion protein partnered with GSK has disappointed in a mid-stage study for biliary tract cancer.
You may also be interested in...
GlaxoSmithKline's market value has slipped in the past three years and the number of failures in the clinic have grown. The major's leadership will be casting nervous glances towards a major shareholder that has a reputation for aggressive restructuring calls.
Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.
While its NDA languishes at the US Food and Drug Administration, the EMA’s CHMP has said yes to dostarlimab’s marketing in the EU for endometrial cancer.